Key Takeaways Sarepta posted an adjusted Q3 loss of $0.13 per share, missing estimates and reversing last year's profit.Revenue fell 15% to $399.4M as Elevidys sales dropped 27% after halted shipments to non-ambulatory patients.The ESSENCE study failed its main goal, sparking a 35% stock plunge and concerns over Sarepta's DMD programs.Sarepta Therapeutics, Inc. (SRPT) reported third-quarter 2025 adjusted loss of 13 cents per share against the Zacks Consensus Estimate for earnings per share (EPS) of one cent ...

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive an ...

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive an ...

Sarepta Therapeutics Inc. (NASDAQ:SRPT) shared topline data from the ESSENCE Phase 3 trial of Amondys 45 (casimersen) and Vyondys 53 (golodirsen) compared with placebo in 225 patients aged 6-13 years with Duchenne muscular dystrophy amenable to exon 45 or 53 skipping.The treatment favored placebo; however, the observed difference of 0.05 steps/second in least-squares means (LSM) did not reach statistical significance (P=0.309) for the primary endpoint, the 4-step ascend velocity at 96 weeks.Also Read: What’ ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock fell sharply Tuesday following disappointing results from a key clinical trial and ongoing concerns about its drug pipeline. However, "Pharma Bro" Martin Shkreli said he still likes the stock. SRPT stock is crashing. See the real-time price action here. Sarepta's Phase 3 ESSENCE study, which tested Amondys 45 and Vyondys 53 as treatments for Duchenne muscular dystrophy, failed to meet its primary endpoint of showing clear benefit over placebo. Read Next: Michae ...

Sarepta Pharmaceuticals Inc (NASDAQ: SRPT) stock is plummeting down, down 31.4% at $16.77 at last glance. Though the biotech company reported an impressive revenue beat, a wider-than-expected loss per share and disappointing trial data for two gene-therapy treatments for Duchenne muscular dystrophy weighed.SRPT is no stranger to outsized moves, having experienced several bear gaps this year. The shares had been creeping higher since their July 24, nine-year low of $10.41 -- with help from the company's rest ...

TESLA WATCH: Elon Musk Pay Deal In Focus Sarepta stock lost almost a third of its value Tuesday on a "mixed bag" third-quarter report that included two drug failures, delayed test results and a sales beat. Sarepta Therapeutics (SRPT) said late Monday it's planning to ask the Food and Drug Administration to grant a traditional approval to Amondys 45 and Vyondys 53 based on evidence of "positive risk-benefits" in treating Duchenne muscular dystrophy. Both drugs are on the market with accelerated approvals, bu ...

Sarepta Therapeutics Inc. shares plunged 37% on Tuesday after the biotechnology company reported disappointing trial results for two of its treatments targeting Duchenne muscular dystrophy (DMD). The ... ...

Palantir跌7.7%，英伟达跌2.0%，遭电影《大空头》的原型人物迈克尔-伯里做空。特斯拉跌3.0%，碰撞 后车门无法开启，五人不幸遇难，特斯拉在美被起诉。优步跌7.3%，Q3调整后EBITDA低于预期。 Beyond Meat续跌9.4%，公司推迟发布第三季财报。Sarepta Therapeutics暴跌36%，其针对杜氏肌营养不 良症的两种基因靶向疗法后期临床试验，未能达到主要研究目标。 来源：滚动播报 ...

盘前交易概况 - 美国东部时间周二上午7:30 盘前交易出现显著活动 早盘价格波动预示着开盘前的潜在机会 [1] - 对于活跃交易者而言 盘前交易为识别潜在突破 反转或剧烈价格波动提供了先机 [1] - 这些早盘动向通常预示着动能可能延续至常规交易时段 使盘前分析成为交易日的关键部分 [1] 盘前涨幅居前股票 - Denny's Corporation (DENN) 上涨49%至6.16美元 [3] - Cambium Networks Corporation (CMBM) 上涨25%至2.55美元 [3] - Tactile Systems Technology, Inc. (TCMD) 上涨22%至19.35美元 [3] - Upwork Inc. (UPWK) 上涨19%至18.60美元 [3] - Kforce Inc. (KFRC) 上涨12%至27.50美元 [3] - Super Group (SGHC) Limited (SGHC) 上涨12%至11.91美元 [3] - Innovex International, Inc. (INVX) 上涨10%至22.62美元 [3] - Sanmina Corporation (SANM) 上涨9%至154.03美元 [3] - Exact Sciences Corporation (EXAS) 上涨8%至72.69美元 [3] - OTG Acquisition Corp. I Class A Ordinary Share (OTGA) 上涨7%至10.77美元 [3] 盘前跌幅居前股票 - Sarepta Therapeutics, Inc. (SRPT) 下跌40%至14.44美元 [4] - JELD-WEN Holding, Inc. (JELD) 下跌32%至2.81美元 [4] - Ichor Holdings, Ltd. (ICHR) 下跌29%至16.05美元 [4] - Insperity, Inc. (NSP) 下跌27%至32.50美元 [4] - Prelude Therapeutics Incorporated (PRLD) 下跌22%至3.08美元 [4] - Forward Industries, Inc. (FORD) 下跌20%至11.11美元 [4] - Navitas Semiconductor Corporation (NVTS) 下跌18%至10.03美元 [4] - Diginex Limited (DGNX) 下跌17%至19.51美元 [4] - Atlas Energy Solutions Inc. (AESI) 下跌16%至10.58美元 [4] - Chijet Motor Company, Inc. (CJET) 下跌15%至3.24美元 [4]